|
Market Closed -
Nasdaq Stockholm
04:00:00 27/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 1.930 SEK | -2.53% |
|
+1.58% | +1.58% |
| 21/10 | Enzymatica AB Signs Distribution Agreement With MedonyX For ColdZyme In Jordan And Iraq | CI |
| 16/10 | STADA Launches Virustad In Germany Based On Enzymatica's ColdZyme Technology | CI |
| Market Cap | 468M 419M 388M 351M 657M 44.57B 668M 4.66B 1.84B 23.31B 1.76B 1.72B 73.81B | P/E 2024 |
-5.73x | P/E 2025 | -8.89x |
|---|---|---|---|---|---|
| Enterprise Value | 436M 390M 361M 327M 612M 41.52B 622M 4.34B 1.72B 21.71B 1.64B 1.6B 68.75B | EV / Sales 2024 |
5.88x | EV / Sales 2025 | 7.96x |
| Free-Float |
56.66% | Yield 2024 * |
-
| Yield 2025 | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| ENZY | Delayed | |
Deutsche Boerse AG
| EN9 | Delayed | |
|
Börse Stuttgart
| EN9 | Delayed | |
|
Boerse Muenchen
| EN9 | Real-time |
| 1 day | -2.53% | ||
| 1 week | +1.58% | ||
| Current month | +12.87% | ||
| 1 month | +15.92% | ||
| 3 months | +2.66% | ||
| 6 months | -31.07% | ||
| Current year | +1.58% |
| 1 week | 1.82 |  | 2.1 |
| 1 month | 1.6 | | 2.1 |
| Current year | 1.55 | | 3.4 |
| 1 year | 1.55 | | 3.4 |
| 3 years | 1.34 | | 5.45 |
| 5 years | 1.34 | | 12 |
| 10 years | 1.34 | | 24.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sana Alajmovic
CEO | Chief Executive Officer | - | 01/02/2026 |
Holger Lembrér
DFI | Director of Finance/CFO | - | 13/04/2026 |
| Chief Tech/Sci/R&D Officer | - | 27/08/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 58 | 15/02/2016 | |
Bengt Baron
CHM | Chairman | 64 | 19/12/2016 |
| Director/Board Member | 71 | 19/12/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/7/26 | Buy | Chief Financial Officer | 50,000 | 0.0206% | ||
| 1/4/26 | Sell | Responsable ventes & marketing | 40,000 | 0.0165% | ||
| 30/12/25 | Buy | Chairman | 20,000 | 0.0082% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.53% | +1.58% | -1.53% | -53.99% | 48.41M | |
| +0.45% | +1.76% | +54.96% | +118.11% | 1,135B | |
| +0.94% | +4.20% | +39.86% | +75.69% | 635B | |
| +0.39% | +0.46% | +25.77% | +97.40% | 505B | |
| +1.43% | +4.56% | +46.20% | +66.91% | 378B | |
| -3.21% | -3.66% | +60.72% | +35.68% | 358B | |
| -0.41% | +2.23% | +22.48% | +48.54% | 295B | |
| +0.23% | +3.28% | +2.57% | +21.89% | 266B | |
| +1.22% | +2.81% | +52.40% | +63.37% | 237B | |
| +1.70% | +1.60% | +31.21% | +102.44% | 193B | |
| Average | -0.03% | +1.86% | +33.46% | +57.60% | 400.37B | |
| Weighted average by Cap. | +0.26% | +1.63% | +41.40% | +81.03% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 45.58M 40.75M 37.7M 34.14M 63.89M 4.34B 64.94M 454M 179M 2.27B 171M 167M 7.18B | 53.9M 48.2M 44.59M 40.38M 75.57M 5.13B 76.81M 537M 212M 2.68B 202M 198M 8.49B |
| Net income | -53.18M -47.55M -43.99M -39.83M -74.55M -5.06B -75.77M -529M -209M -2.65B -200M -195M -8.38B | -51.89M -46.4M -42.93M -38.87M -72.75M -4.94B -73.94M -517M -204M -2.58B -195M -191M -8.18B |
| Net Debt | -73.01M -65.29M -60.4M -54.69M -102M -6.95B -104M -727M -288M -3.63B -274M -268M -11.5B | -32.11M -28.71M -26.57M -24.05M -45.02M -3.06B -45.75M -320M -126M -1.6B -121M -118M -5.06B |
Employees
18
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/10/26 | SEK 1.930 | -2.53% | 128,392 |
| 23/10/26 | SEK 1.980 | +1.80% | 42,693 |
| 22/10/26 | SEK 1.945 | -0.26% | 48,364 |
| 21/10/26 | SEK 1.950 | +0.26% | 124,325 |
| 20/10/26 | SEK 1.945 | +1.83% | 47,296 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- ENZY Stock
Select your edition
All financial news and data tailored to specific country editions
